|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PARRIS N. GLENDENING, Governor
|
|
|
|
|
|
Ch. 18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(III) TO THE EXTENT CONSISTENT WITH FEDERAL AND STATE LAW,
REFLECTS THE INTELLECTUAL PROPERTY POLICIES OF THE INSTITUTION.
(D) A MEMORANDUM OF UNDERSTANDING ESTABLISHED UNDER
SUBSECTION (C)(2) OF THIS SECTION MAY ALLOW FOR THE SELECTION OF A HIGHER
EDUCATION INSTITUTION OR PRIVATE ENTITY TO EXPEDITE THE TRANSLATION OF
CANCER RESEARCH ACTIVITIES INTO TREATMENT PROTOCOLS AND CLINICAL
TRIALS.
(E) THE DEPARTMENT MAY NOT DISTRIBUTE A TOBACCO-RELATED DISEASES
RESEARCH GRANT UNLESS THE DEPARTMENT FIRST DETERMINES THAT:
(1) THE TOBACCO-RELATED DISEASES RESEARCH PLAN WILL HELP
ACHIEVE THE STATE'S PUBLIC HEALTH GOALS;
(2) THE UNIVERSITY OF MARYLAND MEDICAL GROUP WILL NOT USE
ANY PART OF THE GRANT TO SUPPLANT THE FUNDING FOR ANY EXISTING
EDUCATION, SCREENING, TREATMENT AND RESEARCH ACTIVITIES RELATING TO
TOBACCO-RELATED DISEASES OR ANY OTHER TYPE OF CURRENT EXPENDITURE BY
THE INSTITUTION;
(3) THE GRANT WILL BE USED TO CONDUCT RESEARCH IN THE AREAS
SPECIFIED IN SUBSECTION (B) OF THIS SECTION;
(4) THE INSTITUTION HAS EXECUTED A MEMORANDUM OF
UNDERSTANDING AS REQUIRED BY SUBSECTION (C)(2) OF THIS SECTION; AND
(5) THE INSTITUTION SATISFIES ANY OTHER REQUIREMENT
ESTABLISHED BY THE DEPARTMENT AS A CONDITION OF RECEIVING THE GRANT.
(F) EACH YEAR, THE DEPARTMENT SHALL EVALUATE THE EFFICIENCY AND
EFFECTIVENESS OF THE RESEARCH THAT IS CONDUCTED UNDER A
TOBACCO-RELATED DISEASES RESEARCH GRANT.
13-1117 13-1118.
(A) THE DEPARTMENT MAY DISTRIBUTE A MEDICAL INSTITUTION STATEWIDE
ACADEMIC HEALTH CENTER NETWORK GRANT TO THE UNIVERSITY OF MARYLAND
MEDICAL SYSTEM GROUP, AS ALLOCATED IN THE STATE BUDGET, FOR THE PURPOSE
OF ESTABLISHING A STATEWIDE NETWORK AND INFRASTRUCTURE THAT WILL
SUPPORT A WIDE RANGE OF PREVENTION, EDUCATION, OUTREACH, SCREENING,
TREATMENT, AND RESEARCH PROGRAMS RELATING TO TARGETED CANCERS AND
TOBACCO-RELATED DISEASES THAT CAN BE ACCESSED BY INDIVIDUALS
THROUGHOUT THE STATE, INCLUDING;
(1) REGIONAL COORDINATION OF CLINICAL TRIALS SUPPORT SERVICES
AIMED AT INCREASING PARTICIPATION OF DIVERSE POPULATIONS IN CLINICAL
TRIALS;
(2) DEVELOPMENT OF BEST PRACTICES MODELS FOR TO ADDRESS
TARGETED CANCERS AND TOBACCO-RELATED DISEASES, AND
|
|
|
|
|
|
|
|
|
|
- 343 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
